Cargando…

Genetically Engineered Mouse Models for Liver Cancer

Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Kyungjoo, Ro, Simon Weonsang, Seo, Sang Hyun, Jeon, Youjin, Moon, Hyuk, Kim, Do Young, Kim, Seung Up
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016809/
https://www.ncbi.nlm.nih.gov/pubmed/31861541
http://dx.doi.org/10.3390/cancers12010014
_version_ 1783497060728700928
author Cho, Kyungjoo
Ro, Simon Weonsang
Seo, Sang Hyun
Jeon, Youjin
Moon, Hyuk
Kim, Do Young
Kim, Seung Up
author_facet Cho, Kyungjoo
Ro, Simon Weonsang
Seo, Sang Hyun
Jeon, Youjin
Moon, Hyuk
Kim, Do Young
Kim, Seung Up
author_sort Cho, Kyungjoo
collection PubMed
description Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies, a novel approach has been developed to create genetically engineered murine models for HCC, employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor suppressor genes. The versatility of these models is expected to broaden our knowledge of the genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent advances in GEM models of HCC with an emphasis on new technologies.
format Online
Article
Text
id pubmed-7016809
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70168092020-02-28 Genetically Engineered Mouse Models for Liver Cancer Cho, Kyungjoo Ro, Simon Weonsang Seo, Sang Hyun Jeon, Youjin Moon, Hyuk Kim, Do Young Kim, Seung Up Cancers (Basel) Review Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies, a novel approach has been developed to create genetically engineered murine models for HCC, employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor suppressor genes. The versatility of these models is expected to broaden our knowledge of the genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent advances in GEM models of HCC with an emphasis on new technologies. MDPI 2019-12-19 /pmc/articles/PMC7016809/ /pubmed/31861541 http://dx.doi.org/10.3390/cancers12010014 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cho, Kyungjoo
Ro, Simon Weonsang
Seo, Sang Hyun
Jeon, Youjin
Moon, Hyuk
Kim, Do Young
Kim, Seung Up
Genetically Engineered Mouse Models for Liver Cancer
title Genetically Engineered Mouse Models for Liver Cancer
title_full Genetically Engineered Mouse Models for Liver Cancer
title_fullStr Genetically Engineered Mouse Models for Liver Cancer
title_full_unstemmed Genetically Engineered Mouse Models for Liver Cancer
title_short Genetically Engineered Mouse Models for Liver Cancer
title_sort genetically engineered mouse models for liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016809/
https://www.ncbi.nlm.nih.gov/pubmed/31861541
http://dx.doi.org/10.3390/cancers12010014
work_keys_str_mv AT chokyungjoo geneticallyengineeredmousemodelsforlivercancer
AT rosimonweonsang geneticallyengineeredmousemodelsforlivercancer
AT seosanghyun geneticallyengineeredmousemodelsforlivercancer
AT jeonyoujin geneticallyengineeredmousemodelsforlivercancer
AT moonhyuk geneticallyengineeredmousemodelsforlivercancer
AT kimdoyoung geneticallyengineeredmousemodelsforlivercancer
AT kimseungup geneticallyengineeredmousemodelsforlivercancer